Assessment of the Prevalence of Lysosomal Acid Lipase Deficiency in Patients Waiting for a Liver Transplant.
NCT02852304 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2016-08-02
Summary
Lysosomal Acid Lipase (LAL) deficiency is a rare, autosomal recessive storage disease linked to decrease enzymatic activity of LAL, responsible for intracellular accumulation of cholesterol esters and triglycerides.
The accumulation of lipid is in hepatocytes, Kupffer cells and macrophages leading to a fatty liver, hepatic fibrosis that can evolve up to cirrhosis.
LAL deficiency is responsible for significant morbidity and early mortality in children, adolescents and adults in connection with a multi visceral disease reaching the liver, gastrointestinal tract and the vascular endothelium. The disease is caused by homozygous or heterozygous mutations in the gene (LIPA chromosome 10q23.2-23.3) which is responsible for the synthesis of the LAL.
The disease can be diagnosed by enzymatic analysis using few drops of blood absorbed onto blotting paper .
Patients with this deficiency LAL, have no or reduced activity of this enzyme. Because of its rarity, the deficit in LAL is under diagnosed or is diagnosed in patients with liver biological disturbances and / or lipid profile disturbances, steatohepatitis-hepatitis (NASH), the steatosis (NAFLD), the cryptogenic cirrhosis or Wilson disease.
Inclusion period of 12 to 18 months (100 patients).
Conditions
- Patients Waiting for a Liver Transplant.
Sponsors & Collaborators
-
Hospices Civils de Lyon
lead OTHER
Principal Investigators
-
Sylvie Radenne, MD · Hospices Civils de Lyon
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-10-31
- Primary Completion
- 2017-10-31
- Completion
- 2018-03-31
Countries
- France
Study Locations
More Related Trials
-
Influence of Diabetic Control on the Degree of Liver Fibrosis Assessed by Non-invasive Scores in Patients Followed in Diabetology
NCT05605821 ·Status: NOT_YET_RECRUITING
-
LEOPARD Training and Validation Data Collection Study
NCT06675604 ·Status: RECRUITING
-
THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis)
NCT04925362 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
NCT02400216 ·Status: COMPLETED
-
Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD
NCT07313007 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Lanreotide as Treatment of Polycystic Livers
NCT00565097 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland
NCT02846896 ·Status: COMPLETED
-
The Effect of Laparoscopic Splenectomy on Liver Reserve Function for Cirrhosis Patients
NCT05325424 ·Status: RECRUITING ·Phase: NA
-
Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease
NCT00529204 ·Status: TERMINATED ·Phase: PHASE2
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
NCT05832229 ·Status: RECRUITING ·Phase: PHASE2
-
A Physical Activity Program in End-state Liver Disease
NCT02776553 ·Status: COMPLETED ·Phase: NA
-
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
NCT04454463 ·Status: COMPLETED
-
NAFLD and Liver Fibrosis in Obese Adolescents
NCT04561804 ·Status: COMPLETED
-
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
NCT05882032 ·Status: COMPLETED ·Phase: PHASE1
-
Study in Patients With Decompensated Liver Cirrhosis
NCT06380335 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
NCT06007651 ·Status: TERMINATED ·Phase: PHASE1
-
Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes
NCT07270822 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Trial of Faecal Microbiota Transplantation in Cirrhosis
NCT02862249 ·Status: COMPLETED ·Phase: PHASE3
-
REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. the RESUS Proof of Concept Study
NCT05663944 ·Status: COMPLETED ·Phase: PHASE2
-
Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials
NCT01332448 ·Status: COMPLETED
-
An Observational Cohort Study Evaluating Fatty Liver Disease and Liver Fibrosis in Moderate to Severe Psoriasis
NCT02174367 ·Status: UNKNOWN
-
Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
NCT02217345 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation
NCT03468140 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.
NCT05532124 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis
NCT01904058 ·Status: COMPLETED ·Phase: PHASE2